Survey of Oncologists and Dermatologists in Canada on the Management of Acneiform Eruptions Induced by Epidermal Growth Factor Receptor Inhibitors

Rachel Bierbrier; Khashayar Esfahani; Kevin Pehr

doi:10.1177/12034754221119497

Survey of Oncologists and Dermatologists in Canada on the Management of Acneiform Eruptions Induced by Epidermal Growth Factor Receptor Inhibitors

J Cutan Med Surg. 2022 Nov-Dec;26(6):624-625. doi: 10.1177/12034754221119497. Epub 2022 Aug 18.

Authors

Rachel Bierbrier¹, Khashayar Esfahani², Kevin Pehr^{1

3}

Affiliations

¹ 12367 Division of Dermatology, McGill University, Montreal, Canada.
² 1236712367 Departments of Medicine and Oncology, Segal Cancer Centre, Sir Mortimer B. Davis Jewish General Hospital, Rossy Cancer Network, McGill University, Montreal, QC, Canada.
³ 5620 Lady Davis Institute for Medical Research and Division of Dermatology, Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montreal, Canada.

PMID: 35980317
DOI: 10.1177/12034754221119497

No abstract available

Keywords: acneiform eruption; cutaneous adverse event; epidermal growth factor receptor inhibitor; papulopustular eruption; tyrosine kinase inhibitor.

Publication types

Letter

MeSH terms

Acneiform Eruptions* / chemically induced
Acneiform Eruptions* / drug therapy
Antineoplastic Agents* / adverse effects
Dermatologists
ErbB Receptors / adverse effects
Humans
Oncologists*
Protein Kinase Inhibitors

Substances

Protein Kinase Inhibitors
ErbB Receptors
Antineoplastic Agents